Abeona Therapeutics Inc. announced on July 2, 2025, the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million. The transaction officially closed on June 27, 2025. This significant cash infusion follows the PRV being awarded by the U.S. Food and Drug Administration (FDA) in April 2025, in connection with the approval of ZEVASKYN™ (prademagene zamikeracel).
Including the net proceeds from the PRV sale, Abeona reported that its unaudited cash, cash equivalents, restricted cash, and short-term investments as of June 30, 2025, were approximately $225 million. Chief Financial Officer Joe Vazzano stated that this robust financial flexibility ensures over two years of operating capital for sustained growth, without the need for further capital infusion and prior to accounting for ZEVASKYN sales.
The company anticipates the first ZEVASKYN patient treatment in Q3 2025, with profitability projected for early 2026. The successful closure of the PRV sale is a critical milestone that provides Abeona with a strong financial foundation to execute its commercial strategy and advance its pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.